Every 8-K that Pasithea Therapeutics Corp. Warrants (KTTAW) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow KTTAW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KTTAW filings page.
Pasithea Therapeutics Corp. (KTTA) reports that its publicly traded warrants to purchase common stock, which trade on the Nasdaq Capital Market under the symbol KTTAW, will expire on September 17, 2026 in accordance with their terms under the Warrant Agency Agreement with VStock Transfer, LLC.
Any KTTAW warrants not exercised before that date will cease to be exercisable and have no further value. In connection with the expiration, KTTAW will cease trading on Nasdaq and the company will file Form 25 to delist and deregister the warrants, while its common stock will continue trading on Nasdaq under the symbol KTTA.
Pasithea Therapeutics Corp. (KTTA) reported the results of its September 9, 2026 Annual Meeting of Stockholders. Stockholders voted on electing two Class III directors, ratifying the independent auditor, and authorizing a potential reverse stock split.
Of 33,414,448 common shares outstanding and entitled to vote, 26,142,328 were represented, constituting a quorum. Tiago Reis Marques and Lawrence Steinman were elected as Class III directors by plurality. Stockholders ratified the appointment of CBIZ CPAs P.C. as independent registered public accounting firm for the year ending December 31, 2026. Stockholders also approved an amendment to the certificate of incorporation that permits the Board, in its discretion, to implement a reverse stock split of issued common shares at a ratio between 1-for-2 and 1-for-20 at any time up to one year after the Annual Meeting.
Pasithea Therapeutics Corp. (KTTA) reports that Nasdaq has granted an additional 180-day period, until February 16, 2027, to regain compliance with Nasdaq’s $1.00 minimum bid price requirement for continued listing. The initial 180-day grace period had been set to expire on August 19, 2026. The company states it will continue monitoring its share price and may consider actions such as a reverse stock split to regain compliance. If compliance is not achieved within the extended period, Nasdaq may initiate delisting proceedings, which Pasithea would have the right to appeal.
Pasithea Therapeutics Corp. appointed Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer effective May 1, 2026. He will lead clinical development and medical strategy as the company advances its PAS-004 MEK inhibitor program in neurofibromatosis type 1 and other indications.
Under an Executive Employment Agreement dated April 3, 2026, Dr. Krishnan receives an initial $500,000 base salary and is eligible for an annual discretionary bonus of up to 40% of salary, plus participation in benefit plans. On May 1, 2026, the board granted him options to purchase 1,129,323 shares at an exercise price of $0.841 per share, alongside sizable option grants to the CEO, CFO, other employees and non‑employee directors, with multi‑year vesting and full vesting upon a Change in Control.
Pasithea Therapeutics Corp. received a notice from Nasdaq on February 20, 2026 stating that its common stock no longer meets the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market.
The company has 180 calendar days, until August 19, 2026, to regain compliance by having its stock close at or above $1.00 per share for at least ten consecutive business days. If it meets other listing standards, it may qualify for an additional 180-day period and could use actions such as a reverse stock split to cure the deficiency.
If compliance is not regained, Nasdaq staff may move to delist the shares, though the company would have the right to appeal. The company plans to monitor its share price and evaluate options, and states that this notice does not affect its business operations or SEC reporting.
Pasithea Therapeutics Corp. held a special stockholder meeting where investors approved two major share-related changes. Stockholders first approved a certificate amendment increasing authorized common stock from 100,000,000 to 500,000,000 shares, expanding the company’s capacity to issue new equity in the future.
They also approved an amendment to the 2023 Stock Incentive Plan, raising the shares authorized for issuance under the plan by 11,985,779 shares to a new total of 14,000,000 shares. Of 23,091,062 shares outstanding and entitled to vote, 16,746,261 were represented, and both proposals passed by majority vote.
Pasithea Therapeutics Corp. reported the results of its 2025 Annual Meeting of Stockholders held on September 3, 2025. Stockholders approved an amendment to the Company’s 2023 Stock Incentive Plan, increasing the shares authorized for issuance by 1,750,000 shares to a total of 2,014,221 shares.
They also elected two Class II directors to terms ending at the 2028 Annual Meeting and ratified CBIZ CPAs P.C. as independent auditor for the fiscal year ending December 31, 2025. In addition, stockholders approved an amendment to the Certificate of Incorporation authorizing the Board, in its discretion, to implement a reverse stock split of the issued common shares at a ratio between 1-for-2 and 1-for-20 at any time before the one-year anniversary of the meeting. A total of 3,495,116 of 7,443,577 shares outstanding were represented, establishing a quorum.
Pasithea Therapeutics (Nasdaq:KTTA) filed an 8-K reporting receipt of a Nasdaq bid-price deficiency notice on 23-Jun-2025. The company’s shares traded below the $1.00 minimum for 30 consecutive business days, violating Listing Rule 5550(a)(2). Pasithea has 180 days—until 22-Dec-2025—to regain compliance by posting a closing bid of at least $1.00 for 10 straight sessions. A second 180-day extension is possible if other listing standards are met and the firm commits to a remedy such as a reverse split. There is no immediate delisting; business operations and SEC reporting remain unaffected. Management is monitoring share price and evaluating options to restore compliance.